Last Updated : June 30, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Istodax | Romidepsin | Peripheral T-Cell Lymphoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Isturisa | osilodrostat | Endogenous Cushing’s syndrome | Suspended | |||
| Izba | travoprost ophthalmic solution | Glaucoma and ocular hypertension | Reimburse with clinical criteria and/or conditions | Complete | ||
| Jakavi | Ruxolitinib | Polycythemia vera | Reimburse with clinical criteria and/or conditions | Complete | ||
| Jakavi | ruxolitinib | Graft versus host disease | Reimburse with clinical criteria and/or conditions | Complete | ||
| Jakavi | ruxolitinib | Graft versus host disease | Reimburse with clinical criteria and/or conditions | Complete | ||
| Jakavi | Ruxolitinib | Myelofibrosis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Janumet | Sitagliptin phosphate monohydrate / metformin hydrochloride | Diabetes mellitus (Type 2) | List with clinical criteria and/or conditions | Complete | ||
| Januvia | Sitagliptin phosphate | Diabetes mellitus (Type 2) | Do not list | Complete | ||
| Januvia | Sitagliptin phosphate | Diabetes mellitus (Type 2) | List with clinical criteria and/or conditions | Complete | ||
| Jardiance | Empagliflozin | Diabetes mellitus, type 2 | List with clinical criteria and/or conditions | Complete | ||
| Jardiance | Empagliflozin | Diabetes mellitus, type 2 with high cardiovascular risk | Reimburse with clinical criteria and/or conditions | Complete | ||
| Jardiance | empagliflozin | Heart failure | Reimburse with clinical criteria and/or conditions | Complete | ||
| Jemperli | dostarlimab | Endometrial cancer | Reimburse with clinical criteria and/or conditions | Active | ||
| Jemperli | dostarlimab | Endometrial cancer | Do not reimburse | Complete | ||
| Jentadueto | Linagliptin-metformin | Diabetes mellitus, type 2 | List with criteria/condition | Complete | ||
| Jetrea | Ocriplasmin | Vitreomacular adhesion | List with criteria/condition | Complete | ||
| Jinarc | Tolvaptan | Autosomal dominant polycystic kidney disease | Do not list | Complete | ||
| Jorveza | budesonide | Eosinophilic esophagitis, adults | Reimburse with clinical criteria and/or conditions | Complete | ||
| Jorveza | budesonide | Maintenance of Eosinophilic esophagitis in adults | Reimburse with clinical criteria and/or conditions | Complete | ||
| Jublia | efinaconazole | Onychomycosis | Do not reimburse | Complete | ||
| Juluca | Dolutegravir rilpivirine | HIV infection | Reimburse with clinical criteria and/or conditions | Complete | ||
| Jurnista | Hydromorphone hydrochloride | Pain, Chronic (moderate to severe) | Do not list | Complete | ||
| Juxtapid | Lomitapide | Hypercholesterolemia, homozygous familial | Do not list | Complete | ||
| Kadcyla | Trastuzumab Emtansine | Early Breast Cancer (EBC) | Reimburse | Complete |
Last Updated : June 30, 2024